




ICGEB

International Centre for Genetic Engineering and Biotechnology



Studies conducted in collaboration with ICGEB, Italy prove instrumental in initiating Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients

Press Release

“Sun Pharma”, Sun Pharmaceutical Industries Ltd., the world's fourth largest specialty generic, and India's top, pharmaceutical company, has announced the commencement of the Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19.

- Constituting the first phytopharmaceutical drug approved for clinical trial by DCGI for COVID-19
- The Clinical trial will be conducted across 12 centers in India in 210 patients; with results expected by October 2020
- **The Drug has shown anti-SARS-CoV-2 effects in *in-vitro* studies conducted in collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy**

The Company received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trial in April this year.

The clinical trial will be conducted across 12 centres in India in 210 patients. The treatment duration for patients will be 10 days. The results of the clinical trial are expected by October 2020. A human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for Phase II study.

Dilip Shanghvi, Managing Director, Sun Pharma said, “This is the first phytopharmaceutical drug approved for clinical trials by the DCGI as a potential treatment for COVID-19. AQCH has shown anti-SARS-CoV-2 effects in *in-vitro* studies **conducted in collaboration with ICGEB, Italy**. These **results** combined with information on mechanism of action through *in-vitro* and small animal studies give us the confidence to evaluate this **potential treatment option for COVID-19 patients.**”

AQCH, which is being developed for dengue, has shown broad antiviral effect in *in vitro* studies and hence is being tested as a potential treatment option for COVID-19. Since 2016, Sun Pharma has been working very closely with DBT and **ICGEB India**, under the leadership of **Dr. Navin Khanna** and CSIR-IIIM, under the leadership of Dr. Ram Vishwakarma, **to develop a phytopharmaceutical drug for dengue**. The work on evaluation of plant-derived drugs for the treatment of dengue started in 2007 under the auspices of the Department of Biotechnology's (DBT) Task Force on Medicinal and Aromatic Plants.

Dr. Renu Swarup, Secretary of Department of Biotechnology, Ministry of Science and Technology, stated “Our efforts to develop a safe, effective and affordable drug against dengue started about 13 years ago. The collaborating team quickly initiated studies for the development of a drug against COVID-19. I wish the collaborating team success in the conduct of the clinical trial against COVID-19 and for the development of phytopharmaceutical drugs against other infectious diseases.”

Dr. Lawrence Banks, ICGEB Director-General, added “the ICGEB is delighted by this exciting development. The **collaboration between ICGEB New Delhi, and more recently ICGEB Trieste**, with Sun Pharma is a wonderful example of how cutting edge science can translate directly towards improving the lives of people around the world. The alacrity with which ICGEB has been able to contribute towards the global response to the pandemic reflects the strength of our science and our adaptability. We are proud to be part of these activities.”

Dr. Shekhar C Mande, Director General, CSIR commented that “CSIR has had a long-standing association with the pharmaceutical industry in India and welcomes this collaboration with Sun Pharma in taking forward AQCH into clinical trials for COVID-19 patients. This collaboration aligns with our scientific rationale for the quickest way to develop drugs against SARS-CoV-2”.

Press contact: Suzanne Kerbavcic, ICGEB Communications, Public Information and Outreach
Tel: +39-3405971692
Email: kerbav@icgeb.org, press@icgeb.org